Immunome Inc. IMNM
Institutional shares held
45.7 Million
74K
calls
2.04M
puts
Total value of holdings
$462M
$748K
calls
$20.7M
puts
Market Cap
$126M
12,127,400
Shares Out.
Institutional ownership
376.62%
# of Institutions
125
We take great care to ensure that the data presented and summarized in this overview for Immunome Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding IMNM
View all-
T. Rowe Price Investment Management, Inc. Baltimore, MD5.5MShares$57.2 Million0.04% of portfolio
-
Redmile Group, LLC San Francisco, CA4.83MShares$50.2 Million3.87% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA3.88MShares$40.3 Million1.86% of portfolio
-
Black Rock Inc. New York, NY3.76MShares$39.1 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X03.46MShares$35.9 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA3MShares$31.2 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.28MShares$23.7 Million0.0% of portfolio
-
State Street Corp Boston, MA2.13MShares$22.1 Million0.0% of portfolio
-
Opaleye Management Inc. Boston, MA2.04MShares$21.2 Million4.12% of portfolio
-
Jefferies Financial Group Inc. New York, NY2MShares$20.8 Million0.13% of portfolio
Latest Institutional Activity in IMNM
Top Purchases
Top Sells
About IMNM
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
Insider Transactions at IMNM
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 31
2025
|
Clay B Siegall President and CEO |
BUY
Open market or private purchase
|
Direct |
150,000
+18.3%
|
$1,050,000
$7.75 P/Share
|
|
Nov 22
2024
|
Clay B Siegall President and CEO |
BUY
Open market or private purchase
|
Direct |
33,943
+6.13%
|
$305,487
$9.78 P/Share
|
|
Nov 21
2024
|
Clay B Siegall President and CEO |
BUY
Open market or private purchase
|
Direct |
66,057
+11.97%
|
$594,513
$9.54 P/Share
|
|
Nov 21
2024
|
Robert Lechleider Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
15,805
+50.0%
|
$142,245
$9.48 P/Share
|
|
Nov 21
2024
|
Philip Tsai Chief Technology Officer |
BUY
Open market or private purchase
|
Direct |
21,000
+50.0%
|
$189,000
$9.43 P/Share
|
|
Sep 19
2024
|
Max Rosett Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
14,380
-23.25%
|
$230,080
$16.01 P/Share
|
|
Sep 19
2024
|
Max Rosett Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
42,000
+40.44%
|
$42,000
$1.05 P/Share
|
|
Aug 19
2024
|
Jack Higgins Chief Scientific Officer |
SELL
Bona fide gift
|
Direct |
2,471
-15.44%
|
-
|
|
Aug 16
2024
|
Jean Jacques Bienaime |
BUY
Open market or private purchase
|
Direct |
7,000
+29.64%
|
$91,000
$13.94 P/Share
|
|
Aug 15
2024
|
Jack Higgins Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,524
-18.05%
|
$45,812
$13.93 P/Share
|
|
Aug 15
2024
|
Jack Higgins Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
19,524
+50.0%
|
$19,524
$1.35 P/Share
|
|
May 21
2024
|
Jean Jacques Bienaime |
BUY
Open market or private purchase
|
Direct |
2,000
+17.22%
|
$26,000
$13.57 P/Share
|
|
May 21
2024
|
Clay B Siegall President and CEO |
BUY
Open market or private purchase
|
Direct |
20,434
+4.64%
|
$265,642
$13.78 P/Share
|
|
May 20
2024
|
Clay B Siegall President and CEO |
BUY
Open market or private purchase
|
Direct |
79,566
+16.62%
|
$1,034,358
$13.91 P/Share
|
|
Oct 02
2023
|
Clay B Siegall President and CEO |
BUY
Open market or private purchase
|
Direct |
169,204
+34.61%
|
$846,020
$5.91 P/Share
|
|
Oct 02
2023
|
Bruce Turner Chief Strategy Officer |
BUY
Open market or private purchase
|
Direct |
42,300
+50.0%
|
$211,500
$5.91 P/Share
|
|
Oct 02
2023
|
Franklyn G Prendergast Director |
BUY
Grant, award, or other acquisition
|
Direct |
60,840
+50.0%
|
-
|
|
Oct 02
2023
|
Michael Rapp Director |
BUY
Grant, award, or other acquisition
|
Direct |
253,806
+19.16%
|
$1,269,030
$5.91 P/Share
|
|
Jan 15
2023
|
Philip Wagenheim |
BUY
Grant, award, or other acquisition
|
Direct |
8,750
+2.11%
|
$35,000
$4.0 P/Share
|
|
Jan 15
2023
|
Michael Rapp Director |
BUY
Grant, award, or other acquisition
|
Direct |
17,500
+2.1%
|
$70,000
$4.0 P/Share
|
Last 12 Months Summary
Buy / Acquisition
457K
Shares
From
6
Insiders
| Open market or private purchase | 396K shares |
|---|---|
| Exercise of conversion of derivative security | 61.5K shares |
Sell / Disposition
20.4K
Shares
From
3
Insiders
| Bona fide gift | 2.47K shares |
|---|---|
| Open market or private sale | 17.9K shares |